Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry study
Michael Borte, Stefan Raffac, Martin Hrubiško, Karina Jahnz-Rozyk, Enrique Garcia, Barbara McCoy, Shailesh Chavan, Andras Nagy, Leman Yel, Michael Borte, Stefan Raffac, Martin Hrubiško, Karina Jahnz-Rozyk, Enrique Garcia, Barbara McCoy, Shailesh Chavan, Andras Nagy, Leman Yel
Abstract
Aim: Clinical outcomes of women who become pregnant during/after facilitated subcutaneous immunoglobulin (fSCIG) treatment are not well characterized. Materials & methods: This noninterventional, prospective, open-label, post authorization, pregnancy registry study assessed safety outcomes in mothers with primary immunodeficiency diseases who had ever received fSCIG before/during pregnancy and their infants (n = 7). Enrolled women received alternative treatment (arm 1: n = 2) or continued fSCIG (arm 2: n = 7) during pregnancy. Results: No treatment-related adverse events (AEs)/serious AEs (SAEs) were reported. 13 AEs occurred in mothers, including two SAEs (thrombocytopenia, pre-eclampsia; arm 2). A total of 17 AEs occurred in infants, including two SAEs (cleft lip, talipes calcaneovalgus; arm 2) with normal growth/development. Conclusion: Findings provide limited but useful safety data regarding women who received fSCIG before/during pregnancy and the growth/development of their infants. Clinical Trial registration: NCT02556775 (ClinicalTrials.gov); EUPAS5798.
Keywords: IgRT; PID; fSCIG; facilitated subcutaneous immunoglobulin; immunoglobulin-replacement therapy; infant; pregnancy; primary immunodeficiency diseases; real-world data; safety.
Source: PubMed